Loading
Total declarations
Companies
▲ Purchases (4 ops.)
▼ Sales (8 ops.)
Latest filing published 22 May 2026 for Alkermes plc., €47k.
Filing timeline
BuySaleNancy Lurker
Insider track record
Disclosed buys
4
Disclosed sells
8
Signal history
Closed purchases
Market purchases
4
Positive at T+90
25%
Median T+90
-7.7%
Based on 4 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +28.2%Entry US$9.05 · Close at T+365 US$11.60
- +18.0%Entry US$9.50 · Close at T+365 US$11.21
- -54.3%Entry US$18.80 · Close at T+365 US$8.60
- +17.9%Entry US$17.30 · Close at T+365 US$20.40
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Nancy Lurker: trading record in brief
Four purchases, eight sales: Nancy Lurker has open-market trades in both directions, for modest amounts. The purchases weigh EUR 247,566, with a median of EUR 66,820, and make up 33% of open-market trades; the three largest, all at EyePoint, Inc., are dated March 10, 2020 (EUR 91,139), June 14, 2017 (EUR 88,975) and March 29, 2019 (EUR 44,666). The sales, 6 of them with a known amount, add up to EUR 934,332, with a median of EUR 129,280: EUR 381,332 on December 4, 2023 and EUR 176,094 on November 15, 2021 at EyePoint, Inc., then EUR 138,153 on May 13, 2026 at Collegium Pharmaceutical, Inc.
The 61 filings, published between March 18, 2016 and May 22, 2026, are split between EyePoint, Inc. (46, "President & CEO"), Alkermes plc. (10), Collegium Pharmaceutical, Inc (3) and Mallinckrodt plc (2). The record also holds 30 option exercises, 15 grants and 4 filings of another type.
Activity has grown clearly: 14 filings in 2024 and 15 in 2025, against 1 in 2017. Over the last 12 months, 10 filings, 4 of them sales. At EyePoint, Inc., 6 trades by Nancy Lurker fall within 30 days of a trade by Cormorant Asset Management, LP, 3 of them in the same direction.
Companies and markets linked to Nancy Lurker
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations61 total
1,475 shares@ US$36.950.0007% mcap64.6% of flowOrdinary SharesSEC:0001520262-26-000089:1
6,142 sharesOrdinary SharesSEC:0001520262-26-000089:0
4,500 shares@ US$35.96910.018% mcap100.0% of flowCommon StockSEC:0001450485-26-000007:0
901 shares@ US$33.360.0003% mcap35.4% of flowOrdinary SharesSEC:0001520262-26-000070:1
3,751 sharesOrdinary SharesSEC:0001520262-26-000070:0
75,133 shares0Common StockSEC:0001450485-26-000005:0
12,666 shares0Common StockSEC:0001450485-26-000003:0
9,300 shares@ US$15.105114.7% of flowCommon StockSEC:0001450485-25-000009:0
500 shares@ US$14.95Common StockSEC:0001450485-25-000007:1
200 shares@ US$14.950.3% of flowCommon StockSEC:0001450485-25-000007:0
11,111 shares0Common StockSEC:0001562180-25-005390:0
1,924 shares@ US$30.6132.5% of flowOrdinary SharesSEC:0001127602-25-016202:1
8,013 sharesOrdinary SharesSEC:0001127602-25-016202:0
9,791 shares0Common StockSEC:0001062993-25-009809:0
3,752 sharesOrdinary SharesSEC:0001127602-25-012018:2
558 shares@ US$27.008.4% of flowOrdinary SharesSEC:0001127602-25-012018:1
901 shares@ US$27.0013.6% of flowOrdinary SharesSEC:0001127602-25-012018:3
2,323 sharesOrdinary SharesSEC:0001127602-25-012018:0
20,000 shares0Common StockSEC:0001562180-25-001134:0
12,726 shares0Common StockSEC:0001062993-25-001754:0
75,134 shares0Common StockSEC:0001562180-25-000228:1
12,667 shares0Common StockSEC:0001562180-25-000228:0
3,173 shares@ US$7.882.8% of flowCommon StockSEC:0001562180-24-006378:0
Canonical exit: 14 Nov 2024 (T+90)
11,111 shares0Common StockSEC:0001562180-24-005700:0
17,534 shares0Common StockSEC:0001562180-24-001294:1
25 of 61 declarations
